Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A sequential chemotherapy regimen consisting of mFOLFOX6 (modified FOLFOX-6) and FOLFIRI used primarily for metastatic colorectal cancer. mFOLFOX6 includes: - Oxaliplatin (100 mg/m²) administered as a 2-hour infusion - Leucovorin (folinic acid) administered as a 2-hour infusion - Fluorouracil (5-FU) given as both a bolus injection and a 46-hour continuous infusion. FOLFIRI includes: - Irinotecan (180 mg/m²) administered as a 90-minute infusion - Leucovorin (folinic acid) administered as a 2-hour infusion - Fluorouracil (5-FU) given as both a bolus injection and a 46-hour continuous infusion. These regimens are typically administered in 2-week cycles, sequentially rather than simultaneously.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mFOLFOX6 + FOLFIRI.